Effect of Q10 supplementation with statins on lipid profile control

Phase 3

Recruiting

• Conditions: Acute Coronary Syndrome.; Acute ischemic heart disease, unspecified; I24.9

• Registration Number: IRCT20240609062058N1
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Confirmed ACS diagnosis
Age less than 70 years
Complete satisfaction (patient or patient's companion)

Exclusion Criteria

pregnancy
breastfeeding
GFR<30 ml/min
acute kidney injury
Taking any type of supplement or lipid-lowering drug except atorvastatin with a daily dose of 80 mg
underlying liver disease and high liver enzymes in initial tests
Consumption of less than 90% of prescribed supplements
Lack of consent to participate in the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
DL Level. Timepoint: 12 weeks after treatment. Method of measurement: laboratory kit.;HDL Level. Timepoint: 12 weeks after treatment. Method of measurement: laboratory kit.;Triglycerides and Cholesterol Level. Timepoint: 12 weeks after treatment. Method of measurement: laboratory kit.;Myalgia Clinical Index Score. Timepoint: 12 weeks after treatment. Method of measurement: laboratory kit.;LDL/HDL Ratio. Timepoint: 12 weeks after treatment. Method of measurement: laboratory kit.